Blueprint for a Million-Dollar Nest Egg in 4 Years

Gene therapy's comeback kid is massively undervalued with 65% upside potential. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

📱 Do You Use an iPhone? If So... Read This NOW You may have noticed that Apple introduced new email categories: Primary, Transactions, Updates, and Promotions. And many subscribers are finding that their important alerts are going into the wrong category. Don't let Apple sort your emails for you! Click here to ensure you never miss an important update from us. BROUGHT TO YOU BY MANWARD PRESS Dealmaker's Diary: The Rare Disease Fighter Trading at Bargain Prices SPONSORED $100,000 Passive Income Stream Thanks to a little-known alternative investment... One man was able to turn a single $1,000 investment into a $100,000 income stream - over 50 years - without touching a single stock! Click here to find out how <<<   Alpesh Patel Quantitative Investing Specialist Remember when gene therapy was the hot topic? How did we forget that we could literally edit human DNA? Well, their loss is our gain. The stock I want to show you today isn't your average biotech. It's a $5 billion powerhouse tackling rare diseases. SPONSORED While most big tech companies are burning through tens of billions chasing AI hype - with no clear path to profit... ONE STOCK is already way ahead of the game... It's raking in tens of billions in profit per year... CNBC reports it has over 2,000 AI patents... that's more than Tesla, OpenAI, Microsoft and Samsung-combined. And according to Kiplinger, by the start of 2023 it had created more wealth for investors than Nvidia, Oracle, Intel, Taiwan Semiconductor, Facebook and Tesla . Details Here   Unlike most biotech companies, it generates positive cash flow. And the best part - it's incredibly cheap. You're paying just $25 for every $1 in future profits for a biotech company that leverages AI. Get all the details on the company - including the ticker - in today's Dealmaker's Diary. Click here or on the image below to watch. Happy hunting, Alpesh WATCH THE VIDEO (WITH TRANSCRIPT) SPONSORED Why hedge funds, top investors, company insiders and billionaires are dumping the most popular AI stocks... And what they're buying instead. View My Presentation Here   Want more content like this? YES NO

Alpesh Patel Alpesh Patel is an award-winning hedge fund and private equity fund manager, international bestselling author, and entrepreneur. He is the founder and CEO of Praefinium Partners, a Financial Times top FTSE 100 forecaster, and a senior Dealmaker in the U.K.'s Department for International Trade. As a recognized authority on fintech, online trading and venture capital, his past and current client list includes American Express, Merrill Lynch HSBC, Charles Schwab, Goldman Sachs, Barclays... and more.

You are receiving this email because you subscribed to Total Wealth. To unsubscribe from Total Wealth, click here. Need help with your account? Click here. Have a question or comment for the editor? Click here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Manward Press | Attn: Member Services | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.682.5210 | International: +1.443.353.4263 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Total Wealth. © 2025 Manward Press, LLC | All Rights Reserved

Nothing published by Manward Press, LLC should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Manward Press, LLC should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.